Instrument Inactif

Autres langues PHOX BIOT26 Nasdaq

Actions

PBAXU

US71902K2042

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

CERo Therapeutics, Inc. Presents Encouraging Preclinical Data for AML on CER-1236 at Stanford Drug Discovery Symposium Highlighting Tumor Elimination and Manufacturing Attributes	30/04
PHOX BIOT26 : CERo Therapeutics Investor Presentation	25/04
CERo Therapeutics Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02/04
Top Premarket Decliners	11/03
Top Premarket Gainers	08/03
CERo Therapeutics, Inc. Announces Publication of Preclinical Research Supporting the Use of Its Clinical Candidate CER-1236 to Treat AML Patients	07/03
CERo Therapeutics, Inc. Announces Publication of Preclinical Research Supporting the Use of its Clinical Candidate CER-1236 to Treat AML Patients	07/03
CERo Therapeutics Holdings, Inc. announced that it expects to receive $25 million in funding from Arena Business Solutions Global SPC II, Ltd.	23/02
Top Premarket Decliners	20/02
Phoenix Biotech Acquisition Completes Merger With CERo Therapeutics	15/02
Phoenix Biotech Acquisition Corp. Appoints Brian Atwood as Chief Executive Officer	15/02
Phoenix Biotech Acquisition Corp. Announces Executive and Board Changes	15/02
Phoenix Biotech Acquisition Corp. Appoints Charles Carter as Chief Financial Officer	15/02
Phoenix Biotech Acquisition Corp. and CERo Therapeutics, Inc. Announce Close of Business Combination	14/02
Phoenix Biotech Acquisition Corp.(NasdaqGM:CERO) dropped from NASDAQ Composite Index	14/02
Phoenix Biotech Acquisition Corp. completed the acquisition of CERo Therapeutics, Inc.	14/02
CERo Therapeutics Holdings, Inc. announced that it has received $9.4 million in funding	14/02
Phoenix Biotech Acquisition Corp. Sinks 15% in Premarket Activity After Plunging 42% in Wednesday's Regular Trading	08/02
Phoenix Biotech Acquisition Corp. announced that it expects to receive $2 million in funding from Keystone Capital Partners LLC	05/02
Phoenix Biotech Acquisition Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues PHOX BIOT26 Nasdaq

Actions

PBAXU

US71902K2042

Autres langues

Filtres